20 August 2018

DanStem Director Professor Henrik Semb will lead an Institute of Translational Stem Cell Research

appointment

Professor Semb aims to develop safe approaches for up-scaled production of insulin-producing beta cells from human pluripotent stem cells (hPSCs) at the newly established Institute of Translational Stem Cell Research at Helmholtz Zentrum München. This Institute will be part of the objective to develop stem cell-based replacement therapy in type 1 diabetes. Professor Semb will continue to serve as Executive Director and Group Leader at DanStem.

Professor Henrik Semb aims to develop safe approaches for up-scaled production of insulin-producing beta cells from human pluripotent stem cells (hPSCs). He and his team have recently made major breakthroughs towards this goal. 

"We believe that we are well on track with our efforts to develop a cell replacement therapy and that our latest breakthroughs will pave the way for manufacturing of insulin-producing beta cells for initial clinical trials," Henrik Semb.

Professor Semb's long-term objective is to develop a safe and scalable stem cell therapy for people with type 1 diabetes. An important milestone in the short term is the proper production of the cells following defined standards of Good Manufacturing Practice (GMP).

Read the full story published on  Helmholtz Zentrum München website.
Link to Press Release
About Professor Semb
About the Semb Group